Develops oral immunology therapies for autoimmune diseases, focusing on modulating the immune system to treat chronic inflammatory conditions.
Immunic, Inc., a dynamic clinical-stage biopharmaceutical company based in New York, New York, focuses on advancing a pipeline of innovative oral immunology therapies. Specializing in treatments for chronic inflammatory and autoimmune diseases, Immunic is at the forefront of developing transformative medicines. The company's primary developmental effort centers around IMU-838, currently in Phase 2 clinical trials. IMU-838 aims to address conditions such as relapsing-remitting multiple sclerosis, inflammatory bowel disease, and various chronic inflammatory and autoimmune disorders, including potential applications for treating coronavirus disease.
In addition to IMU-838, Immunic is actively progressing with IMU-935, an inverse agonist targeting ROR?t, a key regulator of immune responses. Another promising candidate in its portfolio is IMU-856, designed to restore intestinal barrier function. This therapy targets conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, and immune checkpoint inhibitor induced colitis, underscoring Immunic's commitment to addressing a spectrum of intestinal barrier function diseases.
Founded on a robust scientific foundation, Immunic leverages its expertise in immunology to drive therapeutic innovation. With a strategic focus on oral treatments, the company aims to improve patient outcomes and redefine standards of care in chronic inflammatory and autoimmune diseases. Immunic continues to expand its research efforts and clinical collaborations to advance its mission of delivering effective, accessible therapies for patients worldwide.